Pfizer Inc. (NYSE:PFE) Shares Acquired by Linscomb Wealth Inc.

Linscomb Wealth Inc. lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 5.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 260,291 shares of the biopharmaceutical company’s stock after purchasing an additional 13,934 shares during the period. Linscomb Wealth Inc.’s holdings in Pfizer were worth $6,596,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Clarity Asset Management Inc. acquired a new position in shares of Pfizer during the fourth quarter worth $27,000. Gould Capital LLC raised its holdings in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 493 shares in the last quarter. Bayforest Capital Ltd acquired a new stake in Pfizer in the first quarter valued at $28,000. North Capital Inc. acquired a new stake in Pfizer in the first quarter valued at $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in Pfizer in the fourth quarter valued at $30,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on PFE shares. Bank of America upped their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Leerink Partners cut their price target on shares of Pfizer from $28.00 to $26.00 and set a “market perform” rating on the stock in a report on Wednesday, April 30th. TD Cowen cut their price target on shares of Pfizer from $32.00 to $28.00 and set a “hold” rating on the stock in a report on Tuesday, April 22nd. The Goldman Sachs Group upped their price target on shares of Pfizer from $25.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. Finally, UBS Group boosted their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $28.12.

Pfizer Stock Up 1.4%

Pfizer stock opened at $24.57 on Monday. The company has a 50-day simple moving average of $24.44 and a 200-day simple moving average of $24.48. The firm has a market capitalization of $139.69 billion, a P/E ratio of 13.07, a P/E/G ratio of 0.88 and a beta of 0.52. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.60 earnings per share. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date is Friday, July 25th. Pfizer’s dividend payout ratio is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.